Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – What’s Next?

Shares of Agenus Inc. (NASDAQ:AGEN) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.14 and traded as high as $5.05. Agenus shares last traded at $4.84, with a volume of 1,087,913 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AGEN. Robert W. Baird increased their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th. HC Wainwright raised shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, June 4th. Wall Street Zen upgraded shares of Agenus from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, B. Riley reiterated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $14.00.

Agenus Stock Up 5.9%

The business’s 50-day moving average price is $4.01 and its 200-day moving average price is $3.14. The firm has a market capitalization of $132.71 million, a PE ratio of -0.56 and a beta of 1.51.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million. On average, analysts anticipate that Agenus Inc. will post -12.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently modified their holdings of the company. Barclays PLC grew its stake in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 4,924 shares during the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 5,000 shares in the last quarter. Corton Capital Inc. acquired a new stake in shares of Agenus in the 4th quarter valued at $36,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Agenus by 32.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 15,731 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Agenus in the fourth quarter valued at about $51,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.